Sarepta sinks on FDA report

Investor's Business Daily
November 2013
Investors Business Daily;11/13/2013, pA02
Its stock plunged Tue. after reporting that the FDA issued a negative report on a drug the biotech firm is developing. The FDA said it considered Sarepta's application for its experimental Duchenne muscular dystrophy drug, eteplirsen, to be "premature," the company said.


Related Articles

  • Group Seeks Simpler Regulatory Path for Genetic Disease Drugs. Moran, Nuala // BioWorld International;10/7/2009, Vol. 14 Issue 40, p3 

    The article reports on the ongoing discussion about regulating the commercialization of antisense therapies to treat Duchenne's muscular dystrophy (DMD). DMD experts and a Food and Drug Administration (FDA) representative are discussing ways to deal with the fact that a different antisense...

  • Myth vs. reality: Rare disease drug work tougher than it looks. Boggs, Jennifer // BioWorld Today;2/13/2014, Vol. 25 Issue 30, p1 

    The article presents issues surrounding the development of drugs for rare and orphan diseases as the pathway of choice for pharmaceutical companies. Topics discussed include the perceived advantages of opting for orphan drug development, substantial evidence of effectiveness demanded by the U.S....

  • CEO Spills Exon-Skipper News: Sarepta DMD Filing Next Year. Osborne, Randy // BioWorld Today;7/25/2013, Vol. 24 Issue 141, p1 

    The article reports that Wall Street considers the meeting between the U.S. Food and Drug Administration (FDA) and Sarepta Therapeutics Inc. as not showing enough data leading to a new drug application for eteplirsen, the exon-skipping therapy for Duchenne muscular dystrophy (DMD). The FDA wants...

  • How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. Furlong, Pat; Bridges, John F. P.; Charnas, Lawrence; Fallon, Justin R.; Fischer, Ryan; Flanigan, Kevin M.; Franson, Timothy R.; Gulati, Neera; McDonald, Craig; Peay, Holly; Lee Sweeney, H. // Orphanet Journal of Rare Diseases;Jul2015, Vol. 10 Issue 1, p1 

    Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small populations. In this article, we describe how the Duchenne muscular...

  • BioMarin Drug Gets No Help At FDA Panel. AMY REEVES // Investors Business Daily;11/25/2015, pA04 

    The article reports that the Duchenne muscular dystrophy (DMD) treatment drug called drisapersen of pharmaceutical company BioMarin Pharmaceuticals Inc. has received negative feedback from the panel of U.S. Food & Drug Administration (FDA). It states that the panelists cited the tiny increase in...

  • Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target? KREY, MICHAEL // Investors Business Daily;9/20/2016, p29 

    The article reports on a surge in the stock of Sarepta Therapeutics following the U.S. Food and Drug Agency's (FDA) approval of its drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Topics covered include the possibility that Sarepta will be acquired for eteplirsen and its...

  • Spotlight on newly approved drugs. Vecchione, Anthony // Drug Topics;Oct2016, Vol. 160 Issue 10, p40 

    The article offers information about the drugs approved by the U.S. Food and Drug Administration (FDA). FDA has approved Amjevita as a biosimilar to Ehtmira for multiple inflammatory diseases. FDA has approved Stelara for the treatment of moderately to severely active Crohn's disease in adults....

  • FDA Needs Flexibility in Rare Disease Therapy Approvals.  // Applied Clinical Trials;Dec2016/Jan2017, Vol. 25 Issue 12, p6 

    The article offers information on approvals of flexibility in rare disease by the U.S. Food and Drug Administration (FDA) which includes treatment of duchenne muscular dystrophy by Sarepta's Exondys 51, therapies for treating critical conditions, and views of Robert Califf, FDA Commissioner, on it.

  • FDA Stalls on Accelerated Nod, Seeks More Data on Eteplirsen. Powers, Marie // BioWorld Today;4/17/2013, Vol. 24 Issue 73, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has delayed action on Massachusetts-based Sarepta Therapeutics' new drug application for Eteplirsen for the treatment of Duchenne's muscular dystrophy (DMD). The FDA requested for additional information from the existing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics